mobile nav toggler

investors

Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. Our mission is to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases.

DOWNLOAD THE LATEST PRESENTATION

recent releases
Jun 13, 2019

Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has terminated the public offering of common stock previously announced on June 10, 2019. The termination results from an assessment by...

Jun 10, 2019

Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a registered...

Jun 9, 2019

Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that results from the National...

View All Releases >

current stock price
NASDAQPRVB
NASDAQPRVB

investor relations contacts

For more information contact Kimberly Minarovich or Sam Martin
Argot Partners, 212.600.1902 

EMAIL KIMBERLY

EMAIL SAM

Sign Up For Email Alerts